All data are based on the daily closing price as of December 10, 2025
h
Hisamitsu Pharmaceutical
4530.TSE
26.91 USD
-0.13
-0.48%
Overview
Last close
26.91 usd
Market cap
1.89B usd
52 week high
32.23 usd
52 week low
22.74 usd
Target price
27.59 usd
Valuation
P/E
15.6542
Forward P/E
N/A
Price/Sales
1.8875
Price/Book Value
1.0963
Enterprise Value
1.15B usd
EV/Revenue
1.1641
EV/EBITDA
5.5732
Key financials
Revenue TTM
991.85M usd
Gross Profit TTM
592.45M usd
EBITDA TTM
158.58M usd
Earnings per Share
1.72 usd
Dividend
0.56 usd
Total assets
334.93B usd
Net debt
-101.46B usd
About
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as, external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to Asia, the United States, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.